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Abstract
Background: Peripheral disease (arthritis, enthesitis and dactylitis) and extra-articular disease (uveitis, psoriasis and
inflammatory bowel disease) is common in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis
(nr-axSpA). So far, however, summary data on the prevalence are lacking. The objective of this meta-analysis was to
assess the prevalence of peripheral and extra-articular manifestations in ankylosing spondylitis (AS) and nr-axSpA.
Methods: We performed a systematic literature search to identify publications describing the prevalence of peripheral
and extra-articular disease manifestations in patients with AS and nr-axSpA. We assessed the risk of bias and between-
study heterogeneity, and extracted data. Pooled prevalence and prevalence differences were calculated.
Results: Eight studies comprising 2236 patients with AS and 1242 with nr-axSpA were included: 7 of the studies
were longitudinal cohort studies. There was male predominance in AS (70.4 %, 95 % CI 64.4, 76.0 %) but not in
nr-axSpA (46.8 %, 95 % CI 41.7, 51.9), which was independent of the prevalence of human leukocyte antigen
(HLA)-B27. The prevalence of HLA-B27 was similar in AS (78.0 % (95 % CI 73.9, 81.9 %) and nr-axSpA (77.4 %, 95 % CI 68.
9, 84.9 %)). The pooled prevalence of arthritis (29.7 % (95 % CI 22.4, 37.4 %) versus 27.9 % (95 % CI 16.0, 41.6 %)),
enthesitis (28.8 % (95 % CI 2.6, 64.8) versus 35.4 % (95 % CI 6.1, 71.2)). dactylitis (6.0 % (95 % CI 4.7, 7.5 %) versus 6.0 %
(95 % CI 1.9, 12.0 %)), psoriasis (10.2 % (95 % CI 7.5, 13.2 %) versus 10.9 % (95 % CI 9.1, 13.0 %)) and inflammatory bowel
disease (4.1 % (95 % CI 2.3, 6.5 %) versus 6.4 % (95 % CI 3.6, 9.7 %)) were similar in AS and nr-axSpA. The pooled
prevalence of uveitis was higher in AS (23.0 % (95 % CI 19.2, 27.1 %)) than in nr-axSpA (15.9 % (95 % CI 11.8, 20.4 %)).
Conclusion: Peripheral and extra-articular manifestations are equally prevalent in AS and nr-axSpA, except for
uveitis, which is slightly more prevalent in AS. These data provide evidence for the largely equal nature of disease
manifestations in nr-axSpA and AS.
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Background
Spondyloarthritis (SpA) is a prevalent and potentially dis-
abling form of chronic inflammatory arthritis, affecting
0.5–1.5 % of the Western population [1, 2]. SpA has clas-
sically been subdivided into several subtypes, including an-
kylosing spondylitis (AS), psoriatic arthritis (PsA), reactive
arthritis, arthritis/spondylitis associated with inflammatory
bowel disease (IBD), and undifferentiated SpA. Classifica-
tion criteria for SpA have been developed by the Assess-
ment of SpondyloArthritis International Society (ASAS),
which classifies SpA as axial or peripheral SpA [3–5]. The
axial SpA disease spectrum classifies patients as having ei-
ther ankylosing spondylitis (AS) whether the modified
New York criteria (mNYc) are fulfilled, or as having non-
radiographic axial SpA (nr-axSpA) in the absence of defin-
ite sacroiliac (SI) joint changes on plain radiograph.
Whether nr-axSpA is a different form [6, 7] of AS, an
early form [8–10] of (AS) or two manifestations in the
same disease continuum [11–13] is still subject to de-
bate. There are several reasons to assume that AS and
nr-axSpA should be considered as the same disease.
First, AS and nr-axSpA in general have similar clinical
characteristics, especially when related to disease activity
[9–11]. Patients with AS and nr-axSpA not only have
similar levels of disease activity, they also have a similar
clinical disease course in the absence of tumor necrosis
factor (TNF)α inhibiting treatment, as shown by recent
longitudinal results from the German Spondyloarthritis
Inception Cohort (GESPIC) [14]. Second, patients with
nr-axSpA respond similarly to TNFα inhibiting treatment
[15–18]. Third, radiographic changes only appear after
several years; therefore, the requirement for radiographic
change clearly reduces the sensitivity of the mNYc. Not
only is sensitivity of the mNYc rather limited, but several
studies have shown that scoring of radiographs is subject
to considerable inter-reader and intra-reader variability.
Scoring by both trained readers and local rheumatologists/
radiologists not only yields modest sensitivity and specifi-
city at best, but also has only moderate agreement in the
recognition of radiographic sacroiliitis [19, 20]. These limi-
tations challenge the crucial role of radiographic scoring in
the process of diagnosing AS. Magnetic resonance imaging
(MRI) is increasingly being used to visualize inflammation
in the SI joints, as active inflammatory lesions are evident
on MRI before radiographic lesions are detected [13].
However, MRI also has limitations in terms of scoring
agreement, sensitivity, specificity and costs.
On the other hand, AS is characterized by male pre-
dominance and a higher level of C-reactive protein (CRP)
in comparison to nr-axSpA [9–11]. Other studies suggest
that AS and nr-axSpA differ in their genetics, as in some
studies human leukocyte antigen (HLA)-B27 carriage is
higher in AS than in nr-axSpA [21, 22], whilst other stud-
ies suggest there is no difference in HLA-B27 carriage be-
tween the two [9, 23, 24].
Even though spinal inflammation and structural damage
are the main features of axial SpA, many patients have
concomitant peripheral disease (arthritis, enthesitis,
dactylitis) and/or extra-articular disease (uveitis, IBD,
psoriasis). In AS, previous studies have reported 18–58 %
prevalence of arthritis [9, 11, 25–27], 34–74 % prevalence
of enthesitis of [9, 25] and a 6–8 % prevalence of dacty-
litis [9, 26, 28] (reported at any time during the disease
course). The reported prevalence of uveitis occurring at
some point in time during the course of the disease var-
ies from 22–37 % [25, 27, 29–31], and the prevalence of
IBD is estimated at 4–16 % [27, 30–34] and the prevalence
of psoriasis at 4–9 % [6, 27, 30, 31, 33, 34].
In contrast, the prevalence of peripheral and extra-
articular disease manifestations in nr-axSpA remains less
well-defined. Hypothesizing that AS and nr-axSpA re-
flect subsets of a single disease entity and have similar
disease burden, we performed a meta-analysis of pub-
lished studies of axial SpA in order to assess if the best
available estimate of the prevalence of peripheral and
extra-articular disease manifestations is similar in AS
and nr-axSpA.
Methods
We conducted a literature search by database searching,
citation searching, “pearl growing” [35] and reference list
checking. We performed this systematic review and meta-
analysis in accordance with the Preferred Reporting Items
for Systematic reviews and Meta-Analyses (PRISMA)
guidelines [36].
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Search methods
One of the authors (JdW) performed a systematic lit-
erature search with the assistance of an experienced li-
brarian (RS). We used the following electronic
bibliographical databases: Medline, the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL) and The
Cochrane Library on 1 October 2015 (see Additional
file 1: Table S1 for participants, intervention, control
and outcome (PICO) and search strategy). The search
was performed without language restrictions. In order
to retrieve additional references, we used Citation Pearl
Growing [35]. Furthermore, primary and secondary ref-
erences from retrieved publications were manually
checked to identify additional studies.
One review author (JdW) screened each title and ab-
stract and selected potentially eligible studies. Thereafter,
two review authors (JdW, LvM) independently selected
eligible articles according to predetermined selection cri-
teria. If there was any doubt, the full-text article was
read by the review authors. Consensus of inclusion was
in all cases achieved by discussion. If multiple publications
presented data from the same study population, only
the publication with the largest sample size was included.
Reviews were only included if they presented original
data.
Selection criteria for studies
Studies were included in this meta-analysis if data on
prevalence of peripheral and extra-articular disease man-
ifestations in both AS and nr-axSpA were available. We
included both longitudinal and cross-sectional studies.
Randomized controlled trials and retrospective studies
were not included to avoid selection bias and maximize
the accuracy of the data. Reporting the prevalence of
peripheral and extra-articular disease manifestations did
not necessarily have to be the primary outcome of the
study.
All patients with axSpA had to fulfill the ASAS axial
SpA criteria as defined in 2009 or an equivalent if the
study was conducted before 2009 [3] (a modified version
of the European Spondylarthropathy Study Group (ESSG)
criteria [37]). All patients with AS had to meet the
mNY-criteria for AS [38]. All nr-axSpA patients had to
fulfill the ASAS MRI criteria or the clinical arm of the
ASAS criteria for axial SpA [4] (or an equivalent if the
study was conducted before 2009).
SPondyloArthritis Caught Early (SPACE) cohort study
We added unpublished data to our meta-analysis from
one prospective cohort study. The SPACE cohort was
described in detail previously [23]. In short, the SPACE
cohort is a longitudinal cohort of patients aged 16 years
and older, with chronic back pain for at least 3 months
but less than 2 years, and with onset before the age of
45 years. In this meta-analysis, we added data for all
patients with AS and nr-axSpA included between
January 2009 and 2014 at two of the participating cen-
ters (Academic Medical Center Amsterdam and the
Leiden University Medical Center).
Data extraction and management
Two review authors (JdW, LvM) independently extracted
data using a predesigned form. The following details were
extracted whenever available: first author, name of the
study, country, year of publication, study design, study
characteristics, sample size, mean age of patients, male/
female ratio, mean disease duration, HLA-B27 positivity
and percentage of the cohort in which HLA-B27 was mea-
sured and the timing and prevalence of peripheral and
extra-articular disease manifestations. Whenever data on
certain peripheral or extra-articular disease manifestations
were missing, we contacted the authors of the article con-
cerned. Furthermore, we requested data on the distribu-
tion of male/female participants among HLA-B27-positive
and HLA-B27-negative patients with AS and nr-axSpA.
Assessment of risk of bias
Two review authors (JdW, LvM) assessed the potential
risk of bias in all of the included studies by using the
Methodological evaluation of Observational REsearch
(MORE) checklist [39], which we adapted to our research
question. The MORE checklist includes parameters on
reporting of statement of potential conflicts of interest,
study funding, ethical approval, external validity (was the
gold standard for the diagnosis of AS and nr-axSpA used?
Was there (reporting on) sampling bias?), and internal
validity (how and when was the prevalence of peripheral
or extra-articular disease symptoms measured?).
Assessment of heterogeneity
First, we assessed qualitative heterogeneity across studies
by comparing them according to predefined criteria. Sec-
ond, we evaluated the degree of statistical heterogeneity
and inconsistency by using the T2, Chi
2 and I2 statistics.
Heterogeneity was considered significant at P < 0.10 [40].
I2 values of 25, 50 and 75 % were considered to indicate
low, moderate and high inconsistency, respectively [40].
We used a random effects model for studies that we
considered sufficiently homogeneous to include in the
meta-analysis, as we anticipated there would not be one
true effect size for all studies, despite potential mea-
sured quantitative homogeneity [41].
Data synthesis
We pooled studies in a random-effects model using the
Mantel-Haenszel method, which estimates the between-
study variation by comparing the result of each study
with a Mantel-Haenszel random-effect meta-analysis
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result. Data were calculated as pooled prevalence with
the corresponding 95 % confidence interval (CI) and as
the difference in pooled prevalence between AS and
nr-axSpA, with the corresponding 95 % CI. We performed
data analyses using MetaXL [42] in Microsoft Excel 2010
and Review Manager 5. Forest plots were produced for all
analyses using Review Manager 5, and we adapted these
to our specific needs (to show the difference in prevalence
instead of the difference in risk).
Results
Search
The electronic database search identified 447 articles
(Fig. 1). The use of citation pearl growing resulted in
one additional article. After merging for duplicates and
screening of the titles and abstracts, we completely reviewed
44 unique articles. One article reported retrospective
data. One full-text article could not be retrieved. Five
articles did not report symptoms of peripheral or extra-
articular disease manifestations. In 25 articles, there
was no clear differentiation between AS and nr-axSpA.
Two articles did not use the ASAS and mNY criteria to
classify axial SpA. Eight articles reported data on dupli-
cate cohort studies. Finally, eight studies were included
in the meta-analysis [6, 11, 23, 43–45].
Characteristics of the included studies
Eight studies fulfilled the inclusion criteria. The character-
istics of the enrolled studies are summarized in Table 1.
Seven out of eight studies were longitudinal SpA cohort
studies. One study was a cross-sectional study of 100 con-
secutive patients attending outpatient clinics. In total,
3478 patients were included, of whom 2236 had AS and
1242 had nr-axSpA. Patients with AS fulfilled the mNY
criteria in all studies. Patients with nr-axSpA fulfilled the
ASAS criteria in six out of eight studies. Both GESPIC
and Swiss Clinical Quality Management (SCQM) used the
ASAS criteria with minor modifications, as patients were
included before the development of the ASAS criteria.
The mean symptom duration varied from 1.2 ± 0.6 years
in AS and 1.0 ± 0.7 year in nr-axSpA (Esperanza) to
17.7 ± 12.3 years in AS and 12.1 ± 8.5 years in nr-axSpA
(Wallis). In pooled analysis the male prevalence of AS
was 70.4 % (CI 64.4-76.0 %) and of nr-axSpA it was
46.8 % (CI 41.7, 51.9 %), resulting in a difference in
pooled prevalence of 23.2 % (CI 15.3, 31.1 %). When we
compared the male prevalence of AS and nr-axSpA
among HLA-B27-positive and HLA-B27-negative patients,
the difference in prevalence remained (24.2 % more male
patients among patients with AS who were HLA-B27-
positive (CI 15.1, 32.9 %) and 22.3 % more male patients
among those with AS who were HLA-B27-negative (CI
14.4, 30.0 %)). The pooled prevalence of HLA-B27 did
not differ in AS compared to nr-axSpA, with 78.0 %
prevalence in AS (CI 73.9, 81.9 %) in AS compared to
77.4 % (CI 68.9, 84.9 %) in nr-axSpA.
All eight studies collected information about peripheral
and extra-articular disease manifestations at baseline.
Three out of eight studies (GESPIC, Kiltz and SPACE)
reported patients who currently had, or had ever had,
peripheral and extra-articular manifestations. Three stud-
ies only reported disease manifestations that had ever
occurred (SCQM, Wallis and ESPAC) and two cohort
studies reported only current disease manifestations
(DESIR, Esperanza).
Risk of bias
All published studies (seven out of eight) were published
in journals with an impact factor 3.5. The risk of bias
summary for all studies is shown in Additional file 2:
Table S2. In short, the risk of bias in all studies was
considered sufficiently low to be included in this meta-
analysis. General bias (role of funding, reporting on
ethical approval, conflict of interest) was considered
low in all eight studies. Internal validity was considered
high in three out of eight studies (Esperanza, SCQM
and SPACE) and intermediate in five out of eight studies.
The source of the measure of prevalence of peripheral
or extra-articular disease manifestations was reported
in two of the eight studies (SCQM and SPACE).
Fig. 1 Flow chart of included studies on prevalence of peripheral
and extra-articular disease manifestations in non-radiographic axial
spondyloarthritis and ankylosing spondylitis
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Table 1 Characteristics of the eight included studies.
Name cohort or author nr-axSpA n AS n Study design Year of inclusion Data collection Maximum disease duration
for inclusion, years
Mean symptom duration
nr-axSpA, mean years (SD)
Mean symptom duration
AS, mean years (SD)
GESPIC 226 236 Cohort 2000–2004 Baseline AS: <10; nr-axSpA <5 2.6 (1.7) 5.2 (2.3)
Kiltz 44 56 Cross-sectional Unknown n.a. No 9.4 (9.5) 12.8 (10.7)
DESIR 295 180 Cohort 2007–2010 Baseline <3 1.5 (0.9) 1.6 (0.9)
SCQM 232 838 Cohort 2005–2011 Baseline No 5.5 (1.8–13.7)b 12.7 (6.4–22.7)b
SPACE 58 23 Cohort 2009–2014 Baseline <2 1.1 (0.6) 1.3 (0.7)
Esperanza 182 109 Cohort 2008–2011 Baseline <2 1.0 (1.6) 1.2 (0.5)
Wallis 73 639 Cohort 2003–2012 Baseline No 12.1 (8.5)a 17.7 (12.3)a
ESPAC 132 155 Cohort 2009–2014 Unknown No 5.8 (5.5) 11.7 (7.7)
aMean disease duration. bMedian (interquartile range). Nr-axSpA non-radiographic axial spondyloarthritis, AS ankylosing spondylitis, SD standard deviation, GESPIC GErman SPondyloarthritis Inception Cohort, n.a. not















External validity was considered high in five out of eight
studies (Esperanza, Kiltz, SCQM, SPACE and DESIR),
intermediate in one out of eight studies (ESPAC) and low
in two out of eight studies (GESPIC and Wallis).
Heterogeneity
When comparing all study characteristics as summarized
in Table 1, all eight studies were homogeneous enough
to include in the meta-analysis. Statistical heterogeneity




In pooled analysis the prevalence of current peripheral
arthritis was 22.9 % (CI 5.7, 46.0 %) in AS and 25.2 %
(CI 8.9, 45.7 %) in nr-axSpA, resulting in a difference in
pooled prevalence of 0.7 % (CI –5.4, 6.7 %) favoring AS.
Quantitative heterogeneity was not statistically significant
and the level of inconsistency was moderate (Chi2 = 7.29,
P = 0.12, Tau2 = 0.00, I2 = 45 %). The pooled prevalence of
a history of peripheral arthritis was 29.7 % (CI 22.4,
37.4 %) in AS and 27.9 % (CI 16.0, 41.6 %) in nr-axSpA,
resulting in a difference in pooled prevalence of –3.8 %
(CI –8.8, 1.1 %) favoring nr-axSpA (Fig. 2a). Quantitative
heterogeneity was not statistically significant and the level
of inconsistency was low (Chi2 = 1.25, P = 0.74, Tau2 =
0.00, I2 = 0 %).
Enthesitis
In pooled analysis the prevalence of current enthesitis
was 13.6 % (CI 1.8, 31.8 %) in AS and 19.5 % (CI 7.1,
35.7 %) in nr-axSpA, resulting in a difference in the
pooled prevalence of –4.9 % (CI -10.9, 1.0 %) favoring
nr-axSpA. Quantitative heterogeneity was statistically sig-
nificant and the level of inconsistency was moderate
(Chi2 = 11.37, P = 0.02, Tau2 = 0.00, I2 = 65 %). The
pooled prevalence of a history of enthesitis was 28.8 %
(CI 2.6, 64.8 %) in AS and 35.4 % (CI 6.1, 71.2 %) in
nr-axSpA, resulting in a difference in pooled preva-
lence of –5.4 % (CI -9.7, 0.0 %) favoring nr-axSpA
(Fig. 2b). Quantitative heterogeneity was statistically
significant and the level of inconsistency was moderate
(Chi2 = 12.17, P = 0.03, Tau2 = 0.00, I2 = 34 %).
Dactylitis
In pooled analysis the prevalence of current dactylitis
was 5.6 % (CI 0.0, 16.2 %) in AS and 5.2 % (CI 0.4,
13.7 %) in nr-axSpA, resulting in a difference in pooled
prevalence of –0.5 % (CI -2.6-1.6 %) favoring nr-axSpA.
Quantitative heterogeneity was not statistically significant
and the level of inconsistency was moderate (Chi2 = 3.31,
P = 0.19, Tau2 = 0.00, I2 = 40 %). The pooled prevalence of
a history of dactylitis was 6.0 % (CI 4.7, 7.5 %) in AS
and 6.0 % (CI 1.9, 12.0 %) in nr-axSpA, resulting in a
pooled prevalence difference of –0.9 % (CI -6.7, 4.8 %)
favoring nr-axSpA (Fig. 2c). Quantitative heterogeneity
was statistically significant and the level of inconsistency
was moderate (Chi2 = 7.37, P = 0.03, Tau2 = 0.00, I2 =
73 %).
Uveitis
In pooled analysis the prevalence of current uveitis
prevalence was 5.7 % (CI 1.4-12.2 %) in AS and 6.1 %
(CI 2.8-10.5 %) in nr-axSpA, resulting in a difference
in pooled prevalence of -0.3 % (CI -2.3-1.8 %) favoring
nr-axSpA. Quantitative heterogeneity was not statisti-
cally significant and the level of inconsistency was low
(Chi2 = 3.46, P = 0.48, Tau2 = 0.00, I2 = 0 %). The pooled
prevalence of a history of uveitis was 23.0 % (CI 19.2-
27.1 %) in AS and 15.9 % (CI 11.8-20.4 %) in nr-axSpA,
resulting in a difference in pooled prevalence of 6.2 % (CI
2.7, 9.6 %) favoring AS (Fig. 3a). Quantitative hetero-
geneity was statistically significant and the level of in-
consistency was low (Chi2 = 5.94, P = 0.008, Tau2 = 0.00,
I2 = 16 %).
Psoriasis
In pooled analysis the prevalence of psoriasis was 10.2 %
(CI 7.5, -13.2 %) in AS and 10.9 % (CI 9.1, 13.0 %) in
nr-axSpA, resulting in a difference in pooled prevalence
of –0.7 % (CI –2.9, -1.6 %) favoring nr-axSpA (Fig. 3b).
Quantitative heterogeneity was not statistically significant
and the level of inconsistency was low (Chi2 = 7.01, P =
0.43, Tau2 = 0.00, I2 = 0 %).
Inflammatory bowel disease
Pooled analysis showed an IBD prevalence of 4.1 %
(CI 2.3-6.5 %) in AS and 6.4 % (CI 3.6-9.7 %) in nr-
axSpA, resulting in a pooled prevalence difference of
1.4 % (CI -0.1-2.9 %) favoring AS (Fig. 3c). Quantita-
tive heterogeneity was not statistically significant and
the level of inconsistency was low (Chi2 = 6.17, P = 0.52,
Tau2 = 0.00, I2 = 0 %).
Discussion
In this meta-analysis we have shown that peripheral dis-
ease (arthritis, enthesitis, dactylitis) and extra-articular
disease (uveitis, psoriasis, inflammatory bowel disease)
manifestations are frequent and, with the exception of a
history of uveitis, equally prevalent in AS and nr-axSpA.
Our data on peripheral disease are consistent with
earlier published data on peripheral disease in AS, with
18–58 % prevalence of arthritis [9, 11, 25–27], 34–74 %
prevalence of enthesitis [9, 25] and 6–8 % prevalence of
dactylitis [9, 26, 28] (all reported at any time during the
disease). In one study by Vander Cruyssen et al. the
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prevalence of arthritis (58 %) and enthesitis (50 %) (ever
occurrence) was higher [25]. Longer mean symptom
duration (11 years) and the retrospective reporting in
this study may have caused this difference. Importantly,
the prevalence of peripheral disease in AS was not re-
ported as the primary outcome in any of the AS studies.
Our prevalence data for extra-articular disease were
also in line with previous data on AS, showing 22–37 %
prevalence of uveitis [25, 27, 29–31], 4–16 % prevalence
of IBD [27, 30–34], and 4–9 % prevalence of psoriasis
[6, 27, 30, 31, 33, 34], which all adds to the robustness of
our aggregated estimates. The prevalence of uveitis in
our study population was lower than in the meta-
analyses of Stolwijk et al. and Zeboulon et al., who
reported pooled prevalence of 25.8 % and 32.7 %, re-
spectively [29, 30]. This might be caused by a higher
mean disease duration (15.9 years in the meta-analysis
of Stolwijk et al. and 17.7 years in the meta-analysis of
Zeboulon et al.). Another explanation for this difference
in prevalence is that both review studies also included
clinical trials, enriched with patients with more active
and severe disease.
When we compared patients with AS and nr-axSpA,
HLA-B27 was equally prevalent in patients with nr-axSpA
and AS. Because HLA-B27 is the main entry requirement
for fulfilling the ASAS criteria for nr-axial SpA via the
clinical arm, HLA-B27 might be artificially overrepre-
sented in the nr-axSpA arm. However, the Esperanza
Fig. 2 Prevalence of peripheral manifestations in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. a pooled prevalence
difference of arthritis in patients with ankylosing spondylitis versus non-radiographic axial SpA. b pooled prevalence difference of enthesitis in patients
with ankylosing spondylitis versus non-radiographic axial SpA. c pooled prevalence difference of dactylitis in patients with ankylosing spondylitis versus
non-radiographic axial SpA. GESPIC GErman SPondyloarthritis Inception Cohort, SCQM Swiss Clinical Quality Management, SPACE SPondyloArthritis
Caught Early, M-H Mantel-Haenszel
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cohort differentiated axSpA in AS and nr-axSpA in a
clinical and imaging arm, enabling us to compare the
HLA-B27 prevalence in both arms. There was no statis-
tically significant difference in the prevalence of HLA-
B27 in the imaging arm of nr-axSpA (where HLA-B27
is not required to fulfill the ASAS criteria) and in AS
(58.3 % vs. 67.6 %, respectively) [44], providing evidence
for equal HLA-B27 prevalence in nr-axSpA and AS.
Our data show that AS patients were more frequently
male than nr-axSpA patients (23.2 % difference in preva-
lence). These results are in line with previous studies
showing that male patients with axial SpA have more
structural damage on radiographs than female patients
[11, 46–48]. Because the mNY criteria require radiographic
evidence of sacroiliitis, channeling of male patients occurs.
For nr-axSpA, this channeling does not exist, which is
reflected in the equal gender distribution in nr-axSpA.
Interestingly, when we subcategorized the study popula-
tion in HLA-B27-positive and HLA-B27-negative patients
with AS or nr-axSpA, the male predominance among
patients with AS was the same in HLAB27-positive and
HLAB27-negative patients, challenging the concept of
AS as an HLA-B27-positive driven, predominantly male
disease.
Our study data show that peripheral and extra-articular
disease manifestations are, with the exception of uveitis,
frequent and equally prevalent in AS and nr-axSpA.
These data further support the concept of axial SpA being
one disease continuum irrespective of the presence and
extent of radiographic changes [11–13]. Two important
conclusions can be drawn from this meta-analysis. First,
peripheral and extra-articular disease manifestations sig-
nificantly contribute to the burden of disease in axial SpA.
These results are in contrast with the relatively limited
Fig. 3 Prevalence of extra-articular manifestations in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis. a pooled
prevalence difference of uveitis in patients with ankylosing spondylitis versus non-radiographic axial SpA. b pooled prevalence difference of
psoriasis in patients with ankylosing spondylitis versus non-radiographic axial SpA. c pooled prevalence difference of IBD in patients with
ankylosing spondylitis versus non-radiographic axial SpA. GESPIC GErman SPondyloarthritis Inception Cohort, SCQM Swiss Clinical Quality
Management, SPACE SPondyloArthritis Caught Early, M-H Mantel-Haenszel
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contribution of peripheral and extra-articular disease to
disease monitoring and outcome measurement in axial
SpA. Second, these results show that differentiating be-
tween AS and nr-axSpA is artificial and should therefore
be avoided, especially when selecting patients for research
and treatment. These patients can best be combined into
one group with axial SpA.
Uveitis is less prevalent in nr-axSpA than in AS (with
a difference in the pooled prevalence of 6.2 %). This differ-
ence was not explained by a difference between nr-axSpA
and AS in the prevalence of HLA-B27, as this did not
differ between the two groups. Zeboulon and colleagues
showed that the prevalence of uveitis was higher in
HLA-B27-positive patients [29], although this was not
confirmed by Stolwijk et al. [30] in their meta-analysis
of extra-articular manifestations in AS. The higher preva-
lence of uveitis in AS in this meta-analysis might be ex-
plained by the longer mean disease duration (presuming
that uveitis in axial spondyloarthritis does not necessarily
occur at the start of the disease and thus needs time to de-
velop). This hypothesis is supported by 1) the fact that in
the included cohort studies with longer mean disease
duration there was generally a higher prevalence of a
history of uveitis (Kiltz, SCQM, Wallis): excluding those
cohort studies from the meta-analysis resulted in a non-
significant difference between AS and nr-axSpA in the
prevalence of uveitis (data not shown) and 2) the fact that
the prevalence of current uveitis did not differ between
AS and nr-axSpA.
To our knowledge, this is the first meta-analysis sys-
tematically comparing AS with nr-axSpA. Strengths of
the current study are the systematic approach in which
we have chosen to include only studies that were designed
to compare both disease entities, preferably in a pro-
spective manner. Importantly, we have excluded clinical
trials that included patients who were selected because
of a higher activity and/or severity of their disease
(which would have led to channeling bias).
This study has several limitations. First, summarizing
the prevalence of peripheral and extra-articular disease
manifestations was not the main objective of most of the
primary studies included. This might influence the accur-
acy of reporting these disease manifestations (potential
detection bias). Most studies did not report on how the
different disease manifestations were measured. We
should take into account that the prevalence of some of
the disease manifestations that had ever occurred, were
mainly obtained by collecting historic patient-reported
information (recollection bias). However, the between-
study inconsistency of most of the disease manifestations
was only moderate (arthritis, enthesitis and dactylitis)
or even low (uveitis, psoriasis, IBD), suggesting a sig-
nificant level of agreement. Second, selection bias is an-
other possible weakness of this meta-analysis and, more
importantly, of the included primary studies. We hope-
fully limited the magnitude of selection bias in this
meta-analysis by a thoroughly developed search strat-
egy and other methods to increase finding accuracy
(such as citation pearl growing). Within-study selection
bias might be caused by different approaches to the in-
clusion of patients: early spondyloarthritis cohorts
(such as DESIR and SPACE) possibly include different
patients with shorter disease duration than are included
in large observational SpA cohorts.
Furthermore, by applying the ASAS criteria for axial
SpA, the prevalence of disease manifestations and charac-
teristics might be artificially raised in nr-axSpA, because
they are part of those classification criteria. The higher
prevalence of uveitis in patients with AS, however, does
not support this hypothesis. On the other hand, the longer
mean duration of symptoms in patients with AS when
compared to nr-axSpA in five of the eight included studies
might confound the interpretation of the results of
whether symptoms were ever present, which gives patients
with AS more time to accumulate disease manifestations,
and might increase the prevalence of manifestations that
have ever been present. However, when we left out the
studies with substantial differences in symptom duration,
the results remained unchanged, except for uveitis, for
which the difference no longer remained (data not
shown).
Conclusions
This meta-analysis summarized the prevalence of periph-
eral or extra-articular disease in patients with AS and
nr-axSpA. Awareness of the prevalent nature of these
disease manifestations is important in the diagnostic
process, both for treatment choices and for health-related
quality of life. This meta-analysis provides evidence
for the largely equal nature of disease manifestations
in nr-axSpA and AS, which should have consequences
for research and treatment strategies.
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